Product Information
ICOSAPENT ETHYL 1 GRAM CAPSULE is a generic product labeled by Vitruvias Therapeutics Inc., priced at $0.4408 per EA under NDC 69680018692. Its NADAC has been published 32 times since Feb 25, 2026.
FDA first approved this application on Aug 6, 2025. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
1 g/1
Manufacturer
Vitruvias Therapeutics Inc.NDC
69680018692
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ICOSAPENT ETHYLApproval Type
Generic (ANDA)
FDA Application
ANDA219156FDA Approved
8/6/2025
TE Code
AB
On Market Since
10/20/2025
Price Statistics
The NADAC for ICOSAPENT ETHYL 1 GRAM CAPSULE has been published 32 times since Feb 25, 2026, and over the history we have for it it has declined 4.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.4408 per EA |
|---|---|
| All-time high | $0.4612 (Mar 11, 2026) |
| All-time low | $0.4408 (Sep 23, 2026) |
| 52-week high | $0.4612 |
| 52-week low | $0.4408 |
| Median price | $0.4477 |
| Average price | $0.4488 |
| Largest weekly change | -1.9% (Apr 22, 2026) |
| Weeks tracked | 32 |
| Tracking since | Feb 25, 2026 |
Generic Alternatives
The matcher finds 5 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Vitruvias Therapeutics Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Icosapent Ethyl market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ICOSAPENT ETHYL 1 GRAM CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for ICOSAPENT ETHYL 1 GRAM CAPSULE, manufactured by Vitruvias Therapeutics Inc., is $0.4408 per EA (NDC 69680018692), effective Sep 30, 2026.
How has the price of ICOSAPENT ETHYL 1 GRAM CAPSULE changed over time?
Over the history we have for it, the NADAC for ICOSAPENT ETHYL 1 GRAM CAPSULE has declined 4.4%. It has been tracked across 32 weekly CMS publications since Feb 25, 2026.
What are the highest and lowest recorded NADAC prices for ICOSAPENT ETHYL 1 GRAM CAPSULE?
Since Feb 25, 2026, the NADAC for ICOSAPENT ETHYL 1 GRAM CAPSULE has ranged from a low of $0.4408 (Sep 23, 2026) to a high of $0.4612 (Mar 11, 2026), with a median of $0.4477 per EA.
Are there cheaper alternatives to ICOSAPENT ETHYL 1 GRAM CAPSULE?
5 manufacturers publish a NADAC-priced product with the same active ingredient and strength as ICOSAPENT ETHYL 1 GRAM CAPSULE in a comparable dosage form, but none are currently priced below it.
Who manufactures ICOSAPENT ETHYL 1 GRAM CAPSULE?
ICOSAPENT ETHYL 1 GRAM CAPSULE (NDC 69680018692) is labeled by Vitruvias Therapeutics Inc., and CMS classifies it as a generic product.